Loading...
01/11 03:11
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call presents a mixed picture: while there are headwinds in the BetterHelp segment and uncertainty in margins, there are positive developments such as international growth and strategic partnerships. The Q&A section reveals analysts' concerns about competitive pressures and unclear management responses, particularly in the insurance rollout and growth trajectory. The overall sentiment is balanced by strategic initiatives and the potential for future growth, leading to a neutral stock price prediction.
Consolidated Revenue $631.9 million, near the high end of the guidance range and down 1.6% year-over-year, driven by a decline at BetterHelp, offset to some extent by growth in Integrated Care revenues.
Adjusted EBITDA $69.3 million, at the upper end of the guidance range, representing a margin of 11%. This reflects disciplined cost control and revenue flow-through.
Net Loss Per Share $0.19, compared to a net loss per share of $4.92 in the second quarter of 2024. The prior year included a $4.64 pretax noncash goodwill impairment charge. The current quarter included amortization of intangibles, stock-based compensation, and a discrete tax benefit.
Free Cash Flow $61 million, slightly ahead of the prior year period. On a year-to-date basis, free cash flow increased by $11 million compared to the same period last year.
Integrated Care Segment Revenue $391.5 million, increased 3.7% over the prior year period, driven by growth in visit revenue and strong performance in the international business. Catapult contributed approximately 240 basis points to segment growth, and foreign exchange contributed roughly 50 basis points.
U.S. Integrated Care Membership 102.4 million members, up 11% year-over-year, with U.S. Integrated Care virtual visit volume increasing by 6% versus the prior year period.
Chronic Care Program Enrollment 1.12 million, down versus the first quarter due to a previously discussed contract loss. Excluding this, underlying program enrollment would have increased by a low single-digit percentage sequentially.
BetterHelp Segment Revenue $240.4 million, up slightly sequentially but down year-over-year due to headwinds in the U.S. cash pay business. Foreign exchange contributed approximately 45 basis points to year-over-year growth, while UpLift contributed roughly 100 basis points.
BetterHelp Average Paying Users 388,000, down by roughly 9,000 sequentially and 5% lower versus the second quarter of 2024. U.S. cash pay users saw a high single-digit percentage decline year-over-year.
BetterHelp Adjusted EBITDA $11.9 million, representing a margin of 4.9%, down year-over-year due to lower revenue and incremental investments in the insurance initiative.
Wellbound Launch: Introduced a new employee assistance program offering mental health and well-being support, including online therapy services from BetterHelp and access to other Teladoc services.
Cardiometabolic Health Program Enhancements: Added new connected devices, registered dietitian access, sleep support, and other features to address diabetes, hypertension, and obesity.
AI-Enabled Virtual Sitter Solution: Launched for hospital and health system clients to enhance workforce capacity and patient safety.
Hybrid Care Models: Introduced for public health systems internationally to improve access to primary and emergency care in rural areas.
BetterHelp Insurance Initiative: Soft-launched insurance coverage in one state, aiming to expand access and stabilize growth in the mental health segment.
International Integrated Care Growth: International business now accounts for over 15% of revenue, with steady double-digit growth and new localized market launches.
Operational Excellence: Improved client implementation processes, cost efficiency, and productivity, tracking ahead of savings targets.
Cost Efficiency: Reduced stock-based compensation expenses and administrative costs, achieving $61 million in free cash flow for Q2.
Strategic Acquisitions: Acquired Catapult Health for preventative care and UpLift to support BetterHelp's insurance entry.
Integrated Care Focus: Enhanced offerings in the U.S. to improve clinical outcomes and cost efficiency.
Mental Health Expansion: Increased mental health visits by 13% year-over-year in the U.S. and expanded therapist network for BetterHelp.
Consumer Cash Pay Business Decline: The U.S. cash pay business for BetterHelp is experiencing headwinds, with a high single-digit percentage decline in users year-over-year. This is attributed to softening consumer sentiment, macroeconomic uncertainty, and increased customer acquisition costs.
Insurance Initiative Challenges: The BetterHelp insurance initiative is in its early stages and requires significant investment in infrastructure, payer relationships, and therapist credentialing. The initiative is critical to offsetting cash pay business declines but is not expected to contribute meaningfully to revenue until 2026.
Chronic Care Program Enrollment Decline: Chronic care program enrollment decreased due to a previously discussed contract loss. While sequential growth is expected, the loss has impacted overall enrollment numbers.
Tariff Impact: New tariffs, including a 145% China tariff, are expected to have a $3 million unfavorable impact on adjusted EBITDA in 2025. The company is exploring alternative sourcing arrangements to mitigate this impact.
Increased Operating Expenses: Higher operating expenses, including marketing spend and legal fees, have impacted margins in the Integrated Care segment.
Competitive Pressures in Virtual Care: The proliferation of point solutions in virtual care has added to market fragmentation and complexity, posing challenges to Teladoc's integrated care approach.
Macroeconomic Uncertainty: Softening consumer sentiment and macroeconomic uncertainty are affecting customer acquisition and retention, particularly in the U.S. cash pay business.
Supply Chain Diversification: The company is assessing alternative sourcing arrangements to diversify its supply chain in response to tariff impacts, which could involve additional costs and operational adjustments.
2025 Consolidated Revenue: Expected to be in the range of $2.501 billion to $2.548 billion, with the midpoint increasing slightly versus prior range.
2025 Adjusted EBITDA: Expected to be in the range of $263 million to $294 million, with the midpoint slightly below the previous outlook.
2025 Free Cash Flow: Guidance remains unchanged at $170 million to $200 million.
Integrated Care Segment Revenue Growth: Full year 2025 revenue guidance raised to up 1.75% to 3.25% year-over-year, with Catapult contributing approximately 200 basis points to growth.
Integrated Care Adjusted EBITDA Margin: Narrowed to 14.5% to 15.25% for 2025, slightly up at the midpoint.
BetterHelp Revenue Decline: Expected year-over-year decline of 6.8% to 9.2% in 2025, with approximately $10 million in insurance revenue for 2025.
BetterHelp Adjusted EBITDA Margin: Expected to be 4% to 5.5% for the full year, with the midpoint down 75 basis points versus prior guidance.
Third Quarter 2025 Consolidated Revenue: Expected to be in the range of $614 million to $636 million.
Third Quarter 2025 Adjusted EBITDA: Expected to be in the range of $56 million to $70 million.
BetterHelp Insurance Initiative: Soft launch began in a single state in late June, with plans for a methodical ramp over the next several quarters. Early results are encouraging.
International Growth: Continued growth potential with steady double-digit growth in Integrated Care and plans to evaluate opportunities in new geographies.
Operational Excellence: Focus on cost efficiency, tracking ahead of cost savings and productivity targets, and balancing investments in strategic priorities.
Share Repurchase: The company has a capital allocation priority that includes evaluating share repurchases as a potential use of cash. However, no specific share repurchase program or details were announced during the call.
The earnings call summary shows strong financial metrics with optimistic guidance, particularly in Integrated Care revenue growth. While BetterHelp faces a revenue decline, new initiatives like insurance could offset this. The Q&A session indicates positive analyst sentiment, with management addressing concerns about customer acquisition and integration strategies. Announcements of strategic priorities and operational excellence further bolster confidence. Given the market cap, the stock is likely to see a positive movement of 2% to 8%.
The earnings call presents a mixed picture: while there are headwinds in the BetterHelp segment and uncertainty in margins, there are positive developments such as international growth and strategic partnerships. The Q&A section reveals analysts' concerns about competitive pressures and unclear management responses, particularly in the insurance rollout and growth trajectory. The overall sentiment is balanced by strategic initiatives and the potential for future growth, leading to a neutral stock price prediction.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
